Early central nervous system complications after reduced-intensity stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 8, 2004, Pages 561-568

  Kishi, Yukiko ^a   Miyakoshi, Shigesaburo ^b   Kami, Masahiro ^a   Ikeda, Masayuki ^c   Katayama, Yuta ^a   Murashige, Naoko ^a   Kusumi, Eiji ^b   Yuji, Koichiro ^b   Kobayashi, Kazuhiko ^d   Kato, Daisuke ^b   Hamaki, Tamae ^a   Matsumura, Tomoko ^b   Kim, Sung Won ^a   Morinaga, Shinichi ^b   Mori, Shinichiro ^a   Kanemaru, Mineo ^e   Hayashi, Tatsuyuki ^f   Takaue, Yoichi ^a   Taniguchi, Shuichi ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c Toyama Medical and Pharmaceutical University   (Japan)

^d JR Tokyo General Hospital   (Japan)

^e Higashijyujyo Hospital   (Japan)

^f TOKYO METROPOLITAN POLICE HOSPITAL   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cyclosporine neurotoxicity; Graft versus host disease; Limbic encephalopathy; Umbilical cord

Indexed keywords

BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BONE MARROW; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; DEATH; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMIPARESIS; HLA MATCHING; HUMAN; LOGISTIC REGRESSION ANALYSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METABOLIC ENCEPHALOPATHY; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC NEUROPATHY; RISK FACTOR; SEIZURE; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SYMPTOM; T CELL LEUKEMIA; T CELL LYMPHOMA; UMBILICAL CORD BLOOD; VISUAL DISORDER; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; BRAIN DISEASES, METABOLIC; CENTRAL NERVOUS SYSTEM DISEASES; CEREBROVASCULAR DISORDERS; CORD BLOOD STEM CELL TRANSPLANTATION; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIMBIC ENCEPHALITIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 3543135341     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.05.004     Document Type: Article

References (36)

1. Patchell R.A. White III C.L. Clark A.W. Beschorner W.E. Santos G.W. Neurologic complications of bone marrow transplantation Neurology 35 1985 300-306
2. Graus F. Saiz A. Sierra J. et al. Neurologic complications of autologous and allogeneic bone marrow transplantation in patients with leukemia: a comparative study Neurology 46 1996 1004-1009
3. Wiznitzer M. Packer R.J. August C.S. Burkey E.D. Neurological complications of bone marrow transplantation in childhood Ann Neurol. 16 1984 569-576
4. Mohrmann R.L. Mah V. Vinters H.V. Neuropathologic findings after bone marrow transplantation: an autopsy study Hum Pathol. 21 1990 630-639
5. Gallardo D. Ferra C. Berlanga J.J. et al. Neurologic complications after allogeneic bone marrow transplantation Bone Marrow Transplant. 18 1996 1135-1139
6. de Brabander C. Cornelissen J. Smitt P.A. Vecht C.J. van den Bent M.J. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors J Neurol Neurosurg Psychiatry 68 2000 36-40
7. Sostak P. Padovan C.S. Yousry T.A. Ledderose G. Kolb H.J. Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation Neurology 60 2003 842-848
8. Bleggi-Torres L.F. de Medeiros B.C. Werner B. et al. Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases Bone Marrow Transplant. 25 2000 301-307
9. Openshaw H. Slatkin N.E. Parker P.M. Forman S.J. Immune-mediated myelopathy after allogeneic marrow transplantation Bone Marrow Transplant. 15 1995 633-636
10. Rouah E. Gruber R. Shearer W. Armstrong D. Hawkins E.P. Graft-versus-host disease in the central nervous system. A real entity? Am J Clin Pathol. 89 1988 543-546
11. Slavin S. Nagler A. Naparstek E. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
12. Giralt S. Estey E. Albitar M. et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy Blood 89 1997 4531-4536
13. Saito T. Kanda Y. Kami M. et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma Clin Cancer Res. 8 2002 1014-1020
14. McSweeney P.A. Niederwieser D. Shizuru J.A. et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
15. Xun C.Q. McSweeney P.A. Boeckh M. Storb R.F. Broudy V.C. Thompson J.A. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis Blood 94 1999 3273-3276
16. Mielcarek M. Martin P.J. Leisenring W. et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 2003 756-762
17. Fukuda T. Boeckh M. Carter R.A. et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning Blood 102 2003 827-833
18. Childs R. Chernoff A. Contentin N. et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation N Engl J Med. 343 2000 750-758
19. Bornhauser M. Thiede C. Schuler U. et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin Bone Marrow Transplant. 26 2000 119-125
20. Giralt S. Thall P.F. Khouri I. et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631-637
21. De La Camara R. Tomas J.F. Figuera A. Berberana M. Fernandez-Ranada J.M. High dose busulfan and seizures Bone Marrow Transplant. 7 1991 363-364
22. Bearman S.I. Appelbaum F.R. Buckner C.D. et al. Regimen-related toxicity in patients undergoing bone marrow transplantation J Clin Oncol. 6 1988 1562-1568
23. Provenzale J.M. Graham M.L. Reversible leukoencephalopathy associated with graft-versus-host disease: MR findings AJNR Am J Neuroradiol. 17 1996 1290-1294
24. Bechstein W.O. Neurotoxicity of calcineurin inhibitors: impact and clinical management Transpl Int. 13 2000 313-326
25. Gijtenbeek J.M. van den Bent M.J. Vecht C.J. Cyclosporine neurotoxicity: a review J Neurol. 246 1999 339-346
26. Von Hoff D.D. Phase I clinical trials with fludarabine phosphate Semin Oncol. 17 5 suppl 8 1990 33-38
27. Chun H.G. Leyland-Jones B.R. Caryk S.M. Hoth D.F. Central nervous system toxicity of fludarabine phosphate Cancer Treat Rep. 70 1986 1225-1228
28. Spriggs D.R. Stopa E. Mayer R.J. Schoene W. Kufe D.W. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study Cancer Res. 46 1986 5953-5958
29. Warrell Jr R.P. Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity J Clin Oncol. 4 1986 74-79
30. Merkel D.E. Griffin N.L. Kagan-Hallet K. Von Hoff D.D. Central nervous system toxicity with fludarabine Cancer Treat Rep. 70 1986 1449-1450
31. Vidarsson B. Mosher D.F. Salamat M.S. Isaksson H.J. Onundarson P.T. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease Am J Hematol. 70 2002 51-54
32. Cohen R.B. Abdallah J.M. Gray J.R. Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia Ann Intern Med. 118 1993 114-116
33. Wong R. Beguelin G.Z. de Lima M. et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation Br J Haematol. 122 2003 128-134
34. Miyakoshi S. Yuji K. Kami M. et al. Successful engraftment following reduced-intensity umbilical cord blood transplantation (RI-UCBT) for adult patients with advanced hematologic diseases Clin Cancer Res. 1011 2004 3586-3592
35. Gordon B. Lyden E. Lynch J. et al. Central nervous system dysfunction as the first manifestation of multiple organ dysfunction syndrome in stem cell transplant patients Bone Marrow Transplant. 25 2000 79-83
36. Laughlin M.J. Barker J. Bambach B. et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors N Engl J Med. 344 2001 1815-1822